Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (NVO)
NYSE:NVO
NVO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$45.05 - $139.74
Previous CloseN/A
Volume3.65M
Average Volume (3M)22.52M
Market Cap
$253.12B
Enterprise Value$319.55B
Total Cash (Recent Filing)$18.93B
Total Debt (Recent Filing)$99.27B
Price to Earnings (P/E)15.7
Beta1.09
Next Earnings
Nov 05, 2025EPS Estimate
0.94Last Dividend Ex-Date
Aug 18, 2025Dividend Yield2.65%
Share Statistics
EPS (TTM)0.93
Shares Outstanding3,390,128,000
10 Day Avg. Volume18,033,193
30 Day Avg. Volume22,524,993
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue1.02
Enterprise Value/Gross Profit1.22
Enterprise Value/Ebitda1.87
Forecast
1Y Price Target
$67.86Price Target Upside19.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Market ExpansionApproval in MASH could help to broaden Wegovy's coverage and add an incremental $1.9B in peak WW unadjusted revenues.
Product DevelopmentManagement is excited by the oral sema obesity opportunity which should benefit from a bolstered cash pay option.
Regulatory ApprovalsWegovy's approval in MASH marks a small win in what has been a more difficult year for Novo shares.
Bears Say
CompetitionLilly's Mounjaro & Zepbound are expected to continue to take incremental U.S. share from Ozempic and Wegovy.
Financial GuidanceNovo Nordisk announced a second guidance cut, reflecting continued weakness across the incretin business.
Sales PerformanceLower Wegovy sales expectations were specifically impacted by continued/higher-than-expected compounding in the US market and slower-than-expected market expansion.
Novo Nordisk News
NVO FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was $45.05 and its highest was $139.74 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $253.12B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Nov 05, 2025 which is in 71 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Aug 06, 2025. The company reported $0.929 earnings per share for the quarter, beating the consensus estimate of $0.921 by $0.008.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of $0.412 which represents an annual dividend yield of 2.65%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.94.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $0.929 in its last earnings report, beating expectations of $0.921. Following the earnings report the stock price went down -3.906%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in NVO
Novo Nordisk Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$67.86 (19.09% Upside)
$67.86 (19.09% Upside)
Blogger Sentiment
Bullish
NVO Sentiment 86%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 431.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.7%
Last 30 Days ▲ 18.4%
Last 30 Days ▲ 18.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.54%
12-Months-Change
Fundamentals
Return on Equity
75.95%
Trailing 12-Months
Asset Growth
42.90%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
NVO Company Deck
NVO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Novo Nordisk reported strong sales and profit growth in the first half of 2025, with significant expansion in obesity care and international operations. However, the company lowered its full-year outlook due to challenges in the U.S. market and decreased free cash flow, reflecting both positive achievements and areas of concern.View all NVO earnings summariesNVO Stock 12 Month Forecast
Average Price Target
$67.86
▲(19.09% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.39% Mutual Funds
4.34% Other Institutional Investors
94.18% Public Companies and Individual Investors